Are Treatment Preferences Relevant in Response to Serotonergic Antidepressants and Cognitive-Behavioral Therapy in Depressed Primary Care Patients? Results from a Randomized Controlled Trial Including a Patients’ Choice ArmMergl R.a · Henkel V.b · Allgaier A.-K.c · Kramer D.a · Hautzinger M.d · Kohnen R.e · Coyne J.f · Hegerl U.a
aDepartment of Psychiatry, University of Leipzig, Leipzig, Departments of bPsychiatry and cChild and Adolescent Psychiatry, Ludwig Maximilian University of Munich, Munich, dDepartment of Clinical Psychology, Eberhard Karl University Tübingen, Tübingen, and eRPS Research Germany GmbH, Nuremberg, Germany; fDepartment of Psychiatry, University of Pennsylvania Health System, Philadelphia, Pa., USA
Background: Little is known about the influence of depressed patients’ preferences and expectations about treatments upon treatment outcome. We investigated whether better clinical outcome in depressed primary care patients is associated with receiving their preferred treatment. Methods: Within a randomized placebo-controlled single-centre 10-week trial with 5 arms (sertraline; placebo; cognitive-behavioral group therapy, CBT-G; moderated self-help group control; treatment with sertraline or CBT-G according to patients’ choice), outcomes for 145 primary care patients with mild-to-moderate depressive disorders according to DSM-IV criteria were investigated. Preference for medication versus psychotherapy was assessed at screening using a single item. Post-baseline difference scores for the Hamilton Depression Rating Scale (HAMD-17) were used to assess treatment outcome (mixed-model repeated-measures regression analysis). Results: Depressed patients receiving their preferred treatment (n = 63), whether sertraline or CBT-G, responded significantly better than those who did not receive their preferred therapy (n = 54; p = 0.001). The difference in outcome between both groups was 8.0 points on the HAMD-17 for psychotherapy and 2.9 points on the HAMD-17 for treatment with antidepressants. Results were not explained by differences in depression severity or dropout rates. Conclusions: Patients’ relative preference for medication versus psychotherapy should be considered when offering a treatment because receiving the preferred treatment conveys an additional and clinically relevant benefit (HAMD-17: +2.9 points for drugs; +8.0 points for CBT-G) in outcome.
© 2010 S. Karger AG, Basel
Clinical trials registration number: NCT00226642.
Received: October 23, 2009
Accepted after revision: July 5, 2010
Published online: October 23, 2010
Number of Print Pages : 9
Number of Figures : 1, Number of Tables : 3, Number of References : 35
Psychotherapy and Psychosomatics
Vol. 80, No. 1, Year 2011 (Cover Date: December 2010)
Journal Editor: Fava G.A. (Bologna)
ISSN: 0033-3190 (Print), eISSN: 1423-0348 (Online)
For additional information: http://www.karger.com/PPS